CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Everyone at CCTG would like to congratulate Dr Frances Shepherd who was recently awarded the Lifetime Contribution Prize from the Canadian Cancer Society. She is an international leader in clinical and translational lung cancer research whose work has transformed the standard of care for patients in Canada and around the world.
Researchers are leveraging new technology to identify tiny amounts of cancer cell DNA in the blood (circulating tumour DNA – ctDNA) as an indicator of the presence of otherwise undetectable numbers of residual colon cancer cells after surgical removal of the main tumour.
CCTG is still accepting members for our Equity, Diversity, Inclusivity, Indigenization, Accessibility (EDIIA) Working Groups as we strive to create a more equitable, diverse, inclusive, accessible, and culturally safe community for our network and for our patient participants.
The CCTG HD12 trial is the second study in the RADAR international trial and has recently opened in Canada. Researchers will compare the usual treatment for Hodgkin lymphoma, with a new treatment that takes the standard combination drug treatment replacing one of the drugs with brentuximab vedotin that may be more effective and cause fewer side effects for patients.